TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic Viability

The focus on TAVI cost-effectiveness Brazil has gained attention. The country is assessing the expansion of coverage for transcatheter aortic valve implantation (TAVI). This would include patients with severe aortic stenosis who are classified as low surgical risk (STS-PROM <4%) as a first-line treatment. Despite TAVI demonstrating short-term mortality benefits and favorable safety outcomes, the preliminary recommendation from the National Supplementary Health Agency (ANS) suggested against its inclusion. This is due to considerable uncertainties surrounding long-term safety, durability, and high incremental budget impact.

Comparative Effectiveness and Budget Impact: Core Insights

Central to the agency’s deliberation were comprehensive systematic reviews and randomized clinical trials. These compared TAVI to surgical aortic valve replacement (SAVR) in low-risk patients. Data indicated that TAVI is linked to significantly lower all-cause mortality and cardiac complications within the first 30 days to one year. However, after one year, no statistically significant mortality difference exists compared to surgery. Safety signals favoring TAVI included reductions in major bleeding, acute kidney injury, and new-onset atrial fibrillation. There was a notably higher risk of vascular complications, paravalvular regurgitation, and the requirement for a permanent pacemaker.

Economic modeling estimated a mean annual incremental budget impact of R$429 million. This would be cumulatively over R$2 billion across five years if TAVI coverage is expanded to low-risk patients in the private health sector. The incremental cost-effectiveness ratio (ICER) stood at approximately R$119,500 per quality-adjusted life year (QALY) gained. However, the cost per procedure is significantly higher than SAVR. This leaves uncertainty about the cost-effectiveness threshold pertinent to Brazil’s supplementary health sector. The potential for being “cost-saving” only materializes with substantially lower device acquisition costs. These do not yet reflect the real-world prices in Brazil.

Implications for HEOR, Market Access, and Reimbursement Decisions

The ANS’s unfavorable preliminary recommendation illustrates the challenging balance between rapid innovation adoption and fiscal responsibility. For HEOR and market access professionals, the following reflections are paramount:

First, while TAVI presents procedural and short-term clinical advantages, high upfront costs and uncertain long-term valve durability pose significant risks. This is particularly true for younger low-risk patients who may face reinterventions decades later.

Second, agencies increasingly adopt multi-stakeholder, evidence-tiered approaches to technology assessments. They utilize not only randomized trial data but also cost-effectiveness and real-world budget impact modeling. They often refine coverage policies as new information becomes available. In this context, divergences among expert societies and payer representatives highlight the dynamic nature of national reimbursement discussions.

Third, the willingness-to-pay threshold and local epidemiology fundamentally influence value-for-money assessments. This includes procedural costs and device pricing. Given a projected R$2 billion incremental cost over five years, Brazilian payers grapple with difficult decisions. They must balance improved access to advanced therapies with long-term health system sustainability. This is particularly true amid demographic shifts and the escalating burden of cardiovascular disease.

Finally, this decision emphasizes the necessity for manufacturers and HTA stakeholders to showcase not just comparative effectiveness and safety. They must also show population-specific economic value and strategies to mitigate high budget impacts. There is an implicit need for enhanced long-term studies. These should reflect the “real-world” durability and healthcare utilization of TAVI in younger, lower-risk populations.

In summary, Brazil’s current regulatory stance suggests a prudent approach rather than outright rejection of TAVI for low surgical risk populations. As longitudinal outcomes and economic data accumulate alongside adjustments in device pricing, coverage may eventually expand. For the time being, policy decision-making prioritizes cost containment and allocative efficiency amidst significant uncertainty. This reflects a growing trend in global health technology assessment practices. For further insights, you can visit the source.